Pre-Hospital Ticagrelor in ST-Segment Elevation Myocardial Infarction? Probably Not

JACC: Cardiovascular Interventions

Volumn 9, Issue 7, 2016, Pages 657-659

  McDaniel, Michael ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute coronary syndrome(s); antiplatelet therapy; percutaneous coronary intervention; primary PCI; ST segment elevation myocardial infarction

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; MORPHINE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICAGRELOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AMBULANCE; ANGIOGRAPHY; ANTERIOR MYOCARDIAL INFARCTION; BLEEDING; CARDIOVASCULAR MORTALITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; FALSE POSITIVE RESULT; HUMAN; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHYSICIAN; PRIORITY JOURNAL; REPERFUSION; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; UNITED STATES; HEART INFARCTION; TREATMENT OUTCOME;

ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME;

EID: 84959483784     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.01.014     Document Type: Editorial

References (8)

1. American College of Emergency P, Society for Cardiovascular A, Interventions, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
2. G. Montalescot, A.W. van 't Hof, F. Lapostolle, and et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction N Engl J Med 371 2014 1016 1027
3. 24 analysis J Am Coll Cardiol Intv 9 2016 646 656
4. G. Montalescot, J.F. Lassen, C.W. Hamm, and et al. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study Am Heart J 165 2013 515 522
5. G. Parodi, R. Valenti, B. Bellandi, and et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
6. J. Kubica, P. Adamski, M. Ostrowska, and et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial Eur Heart J 37 2016 245 252
7. D.M. Safley, L. Venkitachalam, K.F. Kennedy, and D.J. Cohen Impact of glycoprotein IIb/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the National Cardiovascular Data Registry J Am Coll Cardiol Intv 8 2015 1574 1582
8. A. Sethi, A. Bajaj, A. Bahekar, and et al. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction-a meta-regression of randomized controlled trials Catheter Cardiovasc Interv 82 2013 171 181